Ponente
Descripción
Non-small cell lung cancer (NSCLC) is the most common and the leading cause of cancer death today. CIMAvax-EGF vaccine has been introduced as an EGF-suppressive immunotherapy and shows promise in improving the survival rate and quality of life of NSCLC patients. Hence, the continued development of this vaccine is of paramount importance to achieve long-term treatment for patients. In this work, the immune response in mice was evaluated using three immunization strategies: (i) three different variants of hydroxyapatite nanoparticles (HANp), (ii) the priming-boosting strategy with the combination of Montanide ISA 51 and HANp and (iii) mixtures of organic and lipid nanoparticles such as VSSP and DPPC:Chol (1:1) liposomes, using CIMAvax-EGF as control. Total IgG anti-EGF titres were between 1:5,000 and 1:10,000. With the priming-boosting strategy, it was shown that it is possible to maintain the immune response during the course of treatment. No differences in the IgG2/IgG1 ratio were observed compared to CIMAvax-EGF, consistent with a Th2 polarization pattern. Antibodies induced with vaccination showed avidity for EGF in each of the experimental groups and inhibition of EGF receptor phosphorylation. Histological evaluation of the muscle tissues showed that the new HANp systems did not affect the injection sites. These results hold promise for the introduction of these new HANp systems as effective candidates for long-term treatment in patients with lung cancer and other tumors of epithelial origin.
Reference
González-Martínez, D.A., González-Ruíz, G., Luzardo-Lorenzo, M.C, Bordallo-León, F., Hechavarría-Luna, Y., Cazañas-Quintana, Y., González-Martínez, E., León-Monzon, K., González-Palomo, A., García-Artalejo, J.A., Morán-Mirabal, J. (2022) Hydroxyapatite Nanoparticles as a Potential Long-Term Treatment of Cancer of Epithelial Origin ACS Applied Nanomaterials, 5(5), DOI URL: https://doi.org/10.1021/acsanm.2c00021.
